Compare Amgen, Inc. (AMGN) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares Core High Dividend ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while iShares Core High Dividend ETF trades at $29.08. The key difference: Amgen, Inc. pays a 2.42% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals.
| AMGN | HDV | |
|---|---|---|
Market Cap | $225.71B | — |
Sector | Health | — |
52-Week High | $417.20 | $29.14 |
52-Week Low | $271.18 | $23.64 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
HDV trades at $28.78, up 0.21% with a bullish technical signal. It yields approximately 3.1% from dividends, with recent payouts in June and July 2026. The ETF focuses on high-quality U.S. large-cap dividend stocks, outperforming the S&P 500 year-to-date by 9 percentage points. News highlights its appeal for retirement income and institutional buying, such as 180 Wealth Advisors increasing its stake by 386.2% in Q2 2026.
The outlook is positive due to strong dividend sustainability and defensive sector weighting, but risks include interest rate sensitivity and concentrated holdings. Analysts favor HDV for income-focused portfolios, citing its quality screening and lower volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
